Please try another search
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Name | Age | Since | Title |
---|---|---|---|
Cecilia Daun Wennborg | 58 | 2017 | Independent Director |
Jennifer Jackson | 68 | 2018 | Independent Director |
Brian M. Stuglik | 62 | 2018 | Independent Director |
Axel Gaston Glasmacher | 60 | - | Member of Clinical Advisory Board |
Jarl Ulf Jungnelius | 70 | 2011 | Independent Director |
Paul G. Richardson | - | - | Member of Clinical Advisory Board |
Christian Jacques | 65 | 2018 | Member of Clinical Advisory Board |
Lori Anne Kunkel | 63 | - | Member of Clinical Advisory Board |
Per Wold-Olsen | 75 | 2018 | Independent Chairman of the Board |
Per Anders Göte Samuelsson | 63 | 2012 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review